Can Biosimilars Reduce Specialty Spending?

Video

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

Recent Videos
Naloxone concept represented by wooden letter tiles.
Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication
Image credit: Gorodenkoff | stock.adobe.com
Pharmacist and Patient in Pharmacy | Image Credit: Gorodenkoff - stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
Related Content
FDA Approval | Image Credit: outchill - stock.adobe.com

FDA Approves Cerliponase Alfa for Expanded Indication of CLN2 Disease

Ashley Gallagher, Associate Editor
July 24th 2024
Article
Pharmacy Focus: What to Know About Medication and Summer Travel

Pharmacy Focus: What to Know About Medication and Summer Travel

July 12th 2024
Podcast
Coagulation Factor VIII, FVIII, an essential blood-clotting protein, also known as anti-hemophilic factor, AHF, 3D illustration

Intravenous Immunoglobulin Temporarily Improves Bleeding in Patients With Acquired Von Willebrand Syndrome

Luke Halpern, Assistant Editor
July 24th 2024
Article
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

June 27th 2024
Podcast
Antibodies that cause autoimmune diseases -- Image credit: Love Employee | stock.adobe.com

Study Results Indicate Potential Method of Reversing Lupus, Opening Doors to Treatment

Gillian McGovern, Assistant Editor
July 22nd 2024
Article
Biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book - Image credit: lexiconimages | stock.adobe.com

Learning the Lingo of Biologics and Biosimilars Is Critical

Jeannette Y. Wick, RPh, MBA, FASCP
July 22nd 2024
Article